Does Dr. IRIS ACOSTA AMEZQUITA have financial conflicts of interest?

Dr. IRIS ACOSTA AMEZQUITA (APN) has received a total of $2,711 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $2,711 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. IRIS ACOSTA AMEZQUITA?

According to CMS Open Payments data, Dr. IRIS ACOSTA AMEZQUITA received funding from NOVARTIS PHARMACEUTICALS CORPORATION ($422), GLAXOSMITHKLINE ($393), and LILLY USA ($369).

Does Dr. IRIS ACOSTA AMEZQUITA receive research grants or speaking fees?

Dr. IRIS ACOSTA AMEZQUITA has received $2,711 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. IRIS ACOSTA AMEZQUITA

APNReal-Time Hydrated

Specialty: Nurse Practitioner, Primary Care

Practice Location: EAST ORANGE, NJ 07017

NPI Number: 1295482610

LIFETIME INDUSTRY VALUE

$2,711

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ACOSTA AMEZQUITA is a verified Nurse Practitioner, Primary Care practitioner based in EAST ORANGE, NJ.

Between 2021 and 2025, Dr. ACOSTA AMEZQUITA had an overall industry promotional and research financial footprint of $2,711 as recorded in the federal CMS Open Payments database.

$2,711 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ACOSTA AMEZQUITA's primary funding source is NOVARTIS PHARMACEUTICALS CORPORATION, which accounts for $422 (representing 15.6% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 1

$422

15.6%

GLAXOSMITHKLINE

Rank 2

$393

14.5%

LILLY USA

Rank 3

$369

13.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.